Serum TRACP 5b is a useful marker for monitoring alendronate treatment: Comparison with other markers of bone turnover

Journal of Bone and Mineral Research

Volumn 20, Issue 10, 2005, Pages 1804-1812

  Nenonen, Arja ^a,b,c   Cheng, Sulin ^d   Ivaska, Kaisa K ^e   Alatalo, Sari L ^e,f   Lehtimäki, Terho ^c   Schmidt Gayk, Heinrich ^g   Uusi Rasi, Kirsti ^b   Heinonen, Ari ^b   Kannus, Pekka ^b,h   Sievänen, Harri ^b   Vuori, Ilkka ^b   Väänänen, H Kalervo ^e   Halleen, Jussi M ^e,i  

^a RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^b UKK INSTITUTE FOR HEALTH PROMOTION RESEARCH   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

^f Finnish Red Cross   (Finland)

^g Laboratory Group   (Germany)

^h TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

ⁱ Pharmatest Services Ltd   (Finland)

Author keywords

Alendronate; Bone markers; Randomized study; TRACP 5b; Treatment monitoring

Indexed keywords

ACID PHOSPHATASE; ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CITRATE CALCIUM; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN; PLACEBO; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROTEIN S CTX; PROTEIN TRACP 5B; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG MONITORING; FEMALE; HUMAN; HUMAN EXPERIMENT; LUMBAR SPINE; NORMAL HUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; STATISTICAL SIGNIFICANCE;

ACID PHOSPHATASE; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; ISOENZYMES; MIDDLE AGED; OSTEOGENESIS; POSTMENOPAUSE; VITAMIN D;

EID: 25444449013     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.050403     Document Type: Article

References (38)

1. Minkin C 1982 Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34:285-290.
2. Yaziji H, Janckila AJ, Lear SC, Martin AW, Yam LT 1995 Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues. Am J Clin Pathol 104:397-402.
3. Hayman AR, Macary P, Lehner PJ, Cox TM 2001 Tartrate-resistant acid phosphatase (Acp 5): Identification in diverse human tissues and dendritic cells. J Histochem Cytochem 49:675-684.
4. Orlando JL, Zirino T, Quirk BJ, Averill BA 1993 Purification and properties of the native form of the purple acid phosphatase from bovine spleen. Biochemistry 32:8120-8129.
5. Ljusberg J, Ek-Rylander B, Andersson G 1999 Tartrate-resistant purple acid phosphatase is synthesized as a latent pro-enzyme and activated by cysteine proteinases. Biochem J 343:63-69.
6. Funhoff EG, Klaassen CHW, Samyn B, Beeumen J, Averill BA 2001 The highly exposed loop region in mammalian purple acid phosphatase controls the catalytic activity. ChemBioChem 2:355-363.
7. Lam KW, Eastlund DT, Li C-Y, Yam LT 1978 Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin Chem 24:1105-1108.
8. Lam KW, Li CY, Yam LT, Desnick IU 1981 Comparison of the tartrate-resistant acid phosphatase in Gaucher's disease and leukemic reticuloendotheliosis. Clin Biochem 14:177-181.
9. Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT 2002 Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 320:49-58.
10. Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Yam LT 2002 Stable expression of human tartrate-resistant acid phosphatase isoforms by CHO cells. Clin Chim Acta 326:113-122.
11. Halleen J, Hentunen TA, Hellman J, Väänänen HK 1996 Human bone tartrate-resistant acid phosphatase: Purification and development of an immunoassay. J Bone Miner Res 11:1444-1452.
12. Janckila AJ, Takahashi K, Sun SZ, Yam LT 2001 Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47:74-80.
13. Nakanishi M, Yoh K, Miura T, Ohasi T, Rai SK, Uchida K 2000 Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. Clin Chem 46:469-473.
14. Janckila AJ, Takahashi K, Sun SZ, Yam LT 2001 Naphtol-ASBI phosphate as a preferred substrate for tartrate-resistant acid phosphatase isoform 5b. J Bone Miner Res 16:788-793.
15. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK 2000 Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J Bone Miner Res 15:1337-1345.
16. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK 2001 Serum Tartrate-resistant acid phosphatase is a specific and sensitive marker of bone resorption. Clin Chem 47:597-600.
17. Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT 2003 Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 41:1052-1059.
18. Koizumi M, Takahashi S, Ogata E 2003 Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23:4095-4099.
19. Mose S, Menzel C, Kurth AA, Obert K, Breidert I, Borowsky K, Böttcher H-D 2003 Tartrate-resistant acid phosphatase as serum marker of bone metabolism in cancer patients. Anticancer Res 23:2783-2788.
20. Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM, Rahemtulla A 2003 Tartrate-resistant acid phosphatase isoform 5b; a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 106:455-457.
21. Martinetti A, Seregni E, Ripamonti C, Ferrari L, De Conno F, Miceli R, Pallotti F, Coliva A, Biancolini D, Bombardieri E 2002 Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. Int J Biol Markers 17:253-258.
22. Koizumi M, Takahashi S, Ogata E 2003 Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer 10:21-27.
23. Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C, Vaiopoulos G, Palermos J, Yataganas X, Goldman J, Rahemtulla A 2003 Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 70:34-42.
24. Voskaridou E, Terpos E, Spina G, Palmeros J, Rahemtulla A, Loutradi A, Loukopoulos D 2003 Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 1234:730-737.
25. Hannon RA, Glowes JA, Eagleton AC, Al Hadari AA, Eastell R, Blumsohn A 2004 Clinical performance of immunoreactive tartrate resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34:187-194.
26. Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, Cheng S, Väänänen HK 2002 Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71:20-25.
27. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Àkesson K, Obrant KJ 2004 Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386-393.
28. Uusi-Rasi K, Kannus P, Cheng S, Sievanen H, Pasanen M, Heinonen A, Nenonen A, Halleen J, Fuerst T, Genant H, Vuori I 2003 Effect of alendronate and exercise on bone and physical performance of postmenopausal women: A randomized controlled trial. Bone 33:132-143.
29. Käkönen SM, Hellman J, Karp M, Laaksonen P, Obrant KJ, Väänänen HK, Lövgren T, Pettersson K 2000 Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serum. Clin Chem 46:332-337.
30. Black D, Duncan A, Robins SP 1988 Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197-203.
31. Sievänen H, Kannus P, Nieminen V, Heinonen A, Oja P, Vuori I 1996 Estimation of various mechanical characteristics of human bone using dual energy x-ray absorptiometry. Bone 18:17-28.
32. Janckila AJ, Nakasato YR, Neustadt DH, Yam LT 2003 Disease-specific expression of tartrate-resistant acid phosphatase isoforms. J Bone Miner Res 18:1916-1919.
33. Hannon R, Blumsohn A, Naylor K, Eastell R 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability. J Bone Miner Res 13:1124-1133.
34. Alatalo SL, Halleen JM, Hentunen TA, Mönkkönen J, Väänänen HK 2000 Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 46:1751-1754.
35. Stepan JJ, Burckhardt P 2002 Serum activity of type 5b ACP and biochemical markers of type I collagen degradation in osteoporotic men with Klinefelter's syndrome treated with an intravenous ibandronate. Calcif Tissue Int 70:279.
36. Alatalo SL, Ivaska KK, Peng Z, Halleen JM, Marks SC Jr, Väänänen HK 2003 Serum tartrate-resistant acid phosphatase 5b and osteocalcin in naturally occurring osteopetrotic rats. J Bone Miner Res 18:S1;SA095.
37. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM 2003 Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schönbergs disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883-890.
38. Stepan JJ, Silinkova-Malkova E, Havranek T, Formankova J, Zichova M, Lachmanova J, Strakova M, Broulik P, Pacovsky V 1983 Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 133:189-200.